This study used data from a multinational phase III randomized, double- blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox®) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.
|Original language||English (US)|
|Number of pages||16|
|Journal||International journal of technology assessment in health care|
|State||Published - Jan 1 1998|
ASJC Scopus subject areas
- Health Policy